| Issue Date | Title | Author(s) |
| Jan-2021 | A discrete choice experiment to understand preferences of patients with type 2 diabetes treated with injectable non-insulinic agents | Darbà, Josep; Ascanio, Meritxell |
| Apr-2019 | Admissions and Cost of Hospitalisation of Phenylketonuria: Spanish Claims Database Analysis | Darbà, Josep; Ascanio, Meritxell |
| Sep-2018 | Budget impact analysis of oral Fisiogen Ferro Forte versus intravenous iron for the management of iron deficiency in chronic kidney disease in Spain | Darbà, Josep; Ascanio, Meritxell |
| Nov-2017 | Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective | Mezquita-Raya, Pedro; Darbà, Josep; Ascanio, Meritxell; Ramírez de Arellano, Antonio |
| 20-Dec-2019 | Cost-effectiveness of insulin degludec versus insulin glargine U100 in patients with type 1 and type 2 diabetes in Portugal: evidence from SWITCH 1&2 trials | Darbà, Josep; Ascanio, Meritxell; Carvalho, Davide; Conde, Vasco; Pedersen, Kasper S. |
| 11-Dec-2020 | Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain | Romero Gómez, Manuel 1967-; Kachru, Nandita; Ascanio, Meritxell; Darbà, Josep; Shreay, Sanatan |
| 23-Apr-2021 | Economic Evaluation of the Use of FeNO for the Diagnosis and Management of Asthma Patients in Primary Care in Sweden | Darbà, Josep; Ascanio, Meritxell; Syk, Jörgen; Alving, Kjell |
| 1-Mar-2021 | Economic impact of dry eye disease in Spain: A multicentre retrospective insurance claims database analysis | Darbà, Josep; Ascanio, Meritxell |
| Mar-2019 | Enzymatic replacement therapy for lysosomal storage disorders: Drug evaluations review in Spain | Darbà, Josep; Ascanio, Meritxell |
| Dec-2020 | Epidemiology, management, and economic impact of acute myeloid leukemia and myelodysplastic syndrome in Spain: a claims database analysis | Marsà, Alícia; Ascanio, Meritxell; Diaz-García, Javier; Darbà, Josep |
| Nov-2022 | Estimating the Cost of Thalassemia Care across the World: A Thalassemia International Federation Model | Eleftheriou, Androulla; Antoniou, Eleni; Darbà, Josep; Ascanio, Meritxell; Angastiniotis, Michael; Farmakis, Dimitrios |
| 1-Apr-2025 | Hepatocellular carcinoma: what are the differential costs compared to the general population? | Darbà, Josep; Ascanio, Meritxell |
| 7-Apr-2021 | Hyperkalaemia management and related costs in chronic kidney disease patients with comorbidities in Spain | Olry de Labry Lima, Antonio; Díaz Castro, Óscar; Romero Requena, Jorge M.; García Díaz-Guerra, M. Reyes; Arroyo Pineda, Virginia; Hija Díaz, Belén de la; Ascanio, Meritxell; Darbà, Josep; Cruzado, Josep M. |
| 27-Feb-2023 | Incidence and medical costs of chronic obstructive respiratory disease in Spanish hospitals: a retrospective database analysis | Darbà, Josep; Ascanio, Meritxell |
| Oct-2019 | The current performance-linked and risk sharing agreement scene in the Spanish region of Catalonia | Darbà, Josep; Ascanio, Meritxell |
| 2019 | Therapy for Gastroenteropancreatic Neuroendocrine Tumors: drug evaluation reports review in Spain | Darbà, Josep; Ascanio, Meritxell |
